ArticleScientific reports2026
Tumor habitat analysis using multiparametric MRI as a noninvasive correlate of longitudinal changes in telomerase activity in recurrent IDH-wildtype glioblastoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Multimodal MRI Habitat and Transformer-Based Pathomics to Predict High-Risk Molecular Subtypes and Explore Biological Mechanisms in Adult Diffuse Gliomas.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Telomerase activity is a surrogate marker of cancer cell biology, and predicting changes in telomerase activity in recurrent diseases could inform the therapeutic insights. Advanced multiparametric MRI (mpMRI) enables tumor characterization and may reveal imaging correlates of telomerase dynamics. We analyzed the tumor habitat and radiomics features derived from preoperative mpMRI obtained at both initial diagnosis and tumor recurrence in 20 patients with recurrent IDH-wildtype glioblastoma. These patients had previously been treated with the standard protocol of radiotherapy and temozolomide. The mpMRI included diffusion- and perfusion-weighted imaging. Longitudinal telomerase activity was measured by telomere repeat amplification protocol assay using tissues obtained from core area of tumor. High initial telomerase activity was associated with a larger volume of hypervascular cellular habitat (p = 0.025) within the enhancing region. Decreased telomerase activity was associated with a smaller volume of hypovascular cellular habitat within the non-enhancing region (p = 0.020), and with the 90th percentile of ADC within the tumor region (p = 0.036 on average). Habitat volume and telomerase activity were significantly associated with progression-free survival (p = 0.010 and p = 0.038, respectively). Additionally, changes in habitat volume were linked to alterations in enhancing tumor volume. Advanced mpMRI-derived habitat volumes and heterogeneity metrics represent promising non-invasive biomarkers of telomerase activity in recurrent glioblastoma, potentially supporting treatment stratification, and surgical planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.